

**RECEIVED
CENTRAL FAX CENTER****JUN 02 2008**

Docket No.: ALEX-P03-060

Application No. 10/736,188
Amendment dated June 2, 2008
Reply to Office Action of April 3, 2008

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-18. (Canceled)

19. (Currently amended) A method of inhibiting downregulation of IL-2 or IFN-gamma in a treating CLL patient comprising:

determining whether OX-2/CD200 is upregulated in a human subject afflicted with CLL; and administering to those subjects in which OX-2/CD200 is upregulated an antibody or antigen-binding fragment thereof that binds to human OX-2/CD200 which is upregulated on CLL cells, said antibody or antigen-binding fragment thereof being administered in an amount effective to inhibit an the downregulation of IL-2 or IFN-gamma ~~immune-suppressing effect of OX-2/CD200~~ in said subject.

20. (Canceled)

21. (Previously presented) A method as in claim 19, wherein the antibody is a monoclonal antibody.

22-42. (Canceled)

43. (Previously presented) A method as in claim 19, wherein the antibody or antigen-binding fragment thereof comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 12; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 23; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 37; a heavy chain CDR1 comprising the sequence

Application No. 10/736,188
Amendment dated June 2, 2008
Reply to Office Action of April 3, 2008

Docket No.: ALEX-P03-060

set forth in SEQ ID NO: 55; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 74; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 93.

44. **(Withdrawn)** A method as in claim 19, wherein the antibody or antigen-binding fragment thereof comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 5; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 21; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 29; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 50; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 69; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 88.

45. **(Withdrawn)** A method as in claim 19, wherein the antibody or antigen-binding fragment thereof comprises a light chain CDR1 comprising the sequence set forth in SEQ ID NO: 13; a light chain CDR2 comprising the sequence set forth in SEQ ID NO: 23; a light chain CDR3 comprising the sequence set forth in SEQ ID NO: 38; a heavy chain CDR1 comprising the sequence set forth in SEQ ID NO: 56; a heavy chain CDR2 comprising the sequence set forth in SEQ ID NO: 75; and a heavy chain CDR3 comprising the sequence set forth in SEQ ID NO: 94.

46-51. **(Canceled)**

52. **(Previously presented)** A method as in claim 19, wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')₂s.

53. **(Previously presented)** A method as in claim 43, wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')₂s.

54. **(Withdrawn)** A method as in claim 44 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')₂s.

Application No. 10/736,188
Amendment dated June 2, 2008
Reply to Office Action of April 3, 2008

Docket No.: ALEX-P03-060

55. **(Withdrawn)** A method as in claim 45 wherein the antibody is selected from the group consisting of humanized antibodies, chimeric antibodies, Fvs, scFvs, Fab's and F(ab')₂s.

56-70. **(Not Entered)**

71-78. **(Cancelled)**